PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

Tom Reed Won’t Seek Re-election, Rules Out Cuomo Challenge

Show Me

‘Dominoes are falling:’ Religious liberty advocates hail end to Minnesota church restrictions

Show Me

Trump Says Biden Border Agenda Has Turned ‘A National Triumph Into a National Disaster’

Show Me

University Abruptly Suspends Diversity Classes: ‘Students Have Been Humiliated and Degraded’

Show Me

Border agents releasing asylum-seeking migrants into US without court date

Show Me

Biden Says He Will Visit Southern Border ‘At Some Point’

Show Me

As Putin lobs counter-digs, can relationship with Biden be saved?

Show Me

Biden Stumbles Then Falls Going Up The Stairs While Boarding Air Force One

Show Me

President Biden Trips Over His Own Feet, Gets Back Up, Falls Again

Show Me

Fair game? Kamala Harris trends after Biden stumbles then falls headed to Air Force One

Show Me

Biden Falls Three Times Getting on Air Force One

Show Me

Reuters first to report Chinese EV trio eye HK listings this year to raise combined $5 billion

Show Me

Hacker Group Says It Accessed Tesla’s, Others’ Internal Video Feeds

Show Me

Volkswagen CEO Says He Wants to ‘Overtake’ Tesla

Show Me

Feds probing nearly two dozen crashes involving Tesla cars

Show Me

China to Restrict Tesla Use by Military and State Personnel

Show Me

Chinese military bans Tesla cars, cites security concerns over onboard cameras

Show Me

Secret Trials in China for Spavor and Kovrig Are ‘Disappointing,’ Trudeau Says

Show Me

Upcoming Protests to Focus on Health, Environmental Impacts of 5G Satellites

Show Me

Alabama House Passes Bill Barring Transgender Athletes From Female Sports Teams

Show Me

Fauci Has ‘Outlived His Usefulness’: Ben Domenech Says Demand For Masks After Vaccines Is ‘Dangerous’

Show Me

Johnson & Johnson working on modified vaccines for COVID-19 variants

Show Me

Democrats Block GOP Bill to Test Illegal Immigrants for COVID-19

Show Me

Judge Dismisses Journalist Lawsuit Against Rod Rosenstein for Allegedly Spying on Her Family

Show Me

Boeing Moon Rocket Passes NASA Test

Show Me

Dr. Shiva: Why I Fight So Hard for ‘One Person, One Vote’

Show Me

Teen boy charged with carjacking ride-share driver; leading police on chase from Illinois to Indiana

Show Me

Israel reports deaths and cases continuing to fall even as the country unlocks

Show Me

Michael Spavor, Canadian Accused of Spying, Stands Trial in China

Show Me

Facebook to develop a version of Instagram for children under 13

Show Me

North Korea Cuts Diplomatic Ties with Malaysia Over U.S. Extradition

Show Me

China: Parents of missing Uyghur children describe horror of family separation

Show Me

Russia the Likely Suspect Behind ‘Nest of Spies’ in Australia: Expert

Show Me

13 Law Enforcement Officers Killed in Mexico Ambush

Show Me

One Man’s Escape From Communist Vietnam

Show Me

UAW Warns Workers Ford Plans to Move Project Worth $900 Million From Ohio to Mexico

Show Me

FEMA to Reimburse $2 Billion in Funeral Costs for Some CCP Virus Victims

Show Me

The Atlanta shootings suspect sought treatment for sex addiction, a former roommate at a halfway house says.

Show Me

Pelosi-Milley Phone Call About ‘Unhinged’ Trump is Target of Judicial Watch Lawsuit

Show Me

“Immoral & Illegal”: U.S. & U.K. Move to Expand Nuclear Arsenals, Defying Global Disarmament Treaties

Show Me